PT900210E - Derivados azahexano heterociclicos com actividade antviral - Google Patents

Derivados azahexano heterociclicos com actividade antviral

Info

Publication number
PT900210E
PT900210E PT97919355T PT97919355T PT900210E PT 900210 E PT900210 E PT 900210E PT 97919355 T PT97919355 T PT 97919355T PT 97919355 T PT97919355 T PT 97919355T PT 900210 E PT900210 E PT 900210E
Authority
PT
Portugal
Prior art keywords
azahexan
antviral
heterocyclic
derivatives
activity
Prior art date
Application number
PT97919355T
Other languages
English (en)
Inventor
Hans-Georg Capraro
Satish Chandra Khanna
Guido Bold
Alexander Fassler
Marc Lang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27171723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT900210(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT900210E publication Critical patent/PT900210E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02Compounds containing any of the groups, e.g. carbazates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02Compounds containing any of the groups, e.g. carbazates
    • C07C281/04Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
PT97919355T 1996-04-22 1997-04-14 Derivados azahexano heterociclicos com actividade antviral PT900210E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH101896 1996-04-22
CH2997 1997-01-08
CH22397 1997-01-31

Publications (1)

Publication Number Publication Date
PT900210E true PT900210E (pt) 2005-06-30

Family

ID=27171723

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97919355T PT900210E (pt) 1996-04-22 1997-04-14 Derivados azahexano heterociclicos com actividade antviral

Country Status (28)

Country Link
EP (1) EP0900210B1 (pt)
JP (1) JP3174347B2 (pt)
CN (3) CN1082508C (pt)
AR (1) AR006720A1 (pt)
AT (1) ATE288903T1 (pt)
AU (1) AU706183B2 (pt)
BR (1) BR9701877A (pt)
CA (3) CA2250840C (pt)
CY (1) CY2596B2 (pt)
CZ (1) CZ296135B6 (pt)
DE (2) DE122005000003I1 (pt)
DK (1) DK0900210T3 (pt)
EA (1) EA001794B1 (pt)
ES (1) ES2238720T3 (pt)
FR (1) FR05C0030I2 (pt)
HK (2) HK1018788A1 (pt)
HU (1) HU224125B1 (pt)
IL (1) IL126381A (pt)
LU (1) LU91189I2 (pt)
MY (1) MY114457A (pt)
NL (1) NL300203I2 (pt)
NO (2) NO313330B1 (pt)
NZ (3) NZ332118A (pt)
PT (1) PT900210E (pt)
SI (1) SI0900210T1 (pt)
SK (1) SK285048B6 (pt)
TW (1) TW409125B (pt)
WO (1) WO1997040029A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
JP2002515501A (ja) * 1998-05-15 2002-05-28 アボット・ラボラトリーズ レトロウイルスプロテアーゼの阻害化合物
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
EP0976736A1 (en) * 1998-07-29 2000-02-02 SUMIKA FINE CHEMICALS Co., Ltd. Production method of 2-(p-alkylphenyl)pyridine compound
ATE239707T1 (de) * 1998-08-07 2003-05-15 Sumika Fine Chemicals Co Ltd 2-phenylpyridine-derivate und verfahren zu deren herstellung
US6255349B1 (en) 1998-12-09 2001-07-03 American Home Products Corporation Alph-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group
US6197803B1 (en) 1998-12-09 2001-03-06 American Home Products Corporation Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine group
US6335350B1 (en) 1998-12-09 2002-01-01 American Home Products Corporation Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses
US6207715B1 (en) 1998-12-09 2001-03-27 American Home Products Corporation Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a substituted phenylene-diamine group
JP4222671B2 (ja) * 1999-02-15 2009-02-12 住友化学株式会社 ヒドラジン誘導体の製造方法
IT1313664B1 (it) 1999-10-12 2002-09-09 Norpharma S P A Processo per la preparazione di un composto aril-piridinico.
US6365745B1 (en) 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
JP4278316B2 (ja) * 2000-07-14 2009-06-10 住友化学株式会社 ヒドラジン誘導体の製造方法
WO2004037790A1 (en) 2002-10-02 2004-05-06 Euticals Prime European Therapeuticals Spa Process for the preparation of aryl-piridyl compounds
US7943593B2 (en) * 2002-12-06 2011-05-17 Vertex Pharmaceuticals Incorporated Compositions comprising inhibitors of IMPDH enzyme
ITMI20032338A1 (it) * 2003-11-28 2005-05-29 Dinamite Dipharma S P A In Forma A Bbreviata Diph Composti feniltetrazolici.
CN1980666B (zh) * 2004-05-04 2011-03-30 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
ATE429417T1 (de) 2005-02-10 2009-05-15 Medivir Ab Hiv-protease-inhibitoren
US7723380B2 (en) 2006-07-21 2010-05-25 Gilead Sciences, Inc. Antiviral protease inhibitors
WO2008156632A1 (en) * 2007-06-12 2008-12-24 Concert Pharmaceuticals, Inc. Azapeptide derivatives
WO2009130534A1 (en) * 2008-04-24 2009-10-29 Oxyrane (Pty) Ltd. Process for synthesizing atazanavir
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
EP2272831A1 (en) 2009-06-26 2011-01-12 Prime European Therapeuticals S.p.A. Process for the preparation of arylpyridinyl compounds
WO2011037467A1 (en) 2009-09-28 2011-03-31 Stichting Katholieke Universiteit Atazanavir for treating inflammatory diseases
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
US20130005780A1 (en) * 2010-03-01 2013-01-03 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EA201390464A1 (ru) 2010-09-28 2013-08-30 Рациофарм Гмбх Способ сухой обработки атазанавира
US20140343290A1 (en) * 2011-07-27 2014-11-20 Rakesh Kumar Singh Process for the preparation of atazanavir or its bisulfate salt
KR102186030B1 (ko) 2012-10-29 2020-12-03 시플라 리미티드 항 바이러스성 포스포네이트 유사체 및 이의 제조를 위한 방법
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN104163787A (zh) * 2014-08-08 2014-11-26 山东威智医药工业有限公司 阿扎那韦及其硫酸盐的制备方法
CN107459496B (zh) * 2016-06-03 2022-07-19 华东理工大学 噻唑类衍生物在治疗病毒感染中的应用
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN107245052A (zh) * 2017-06-21 2017-10-13 连云港杰瑞药业有限公司 一种阿扎那韦制备方法
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN109574916A (zh) * 2018-12-29 2019-04-05 常州吉恩药业有限公司 阿扎那韦中间体2-[4-(2-吡啶基)苄基]-肼羧酸叔丁酯的工业化生产方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN113603634B (zh) * 2021-08-06 2023-03-21 江苏八巨药业有限公司 一种阿扎那韦中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
ES2093237T3 (es) * 1991-07-03 1996-12-16 Ciba Geigy Ag Derivados de hidrazina farmacologicamente activos y procedimiento para su obtencion.
DK0604368T3 (pt) * 1992-12-23 1997-02-24 Ciba Geigy Ag
KR100333016B1 (ko) * 1992-12-29 2002-11-22 아보트 러보러터리즈 레트로바이러스성프로테아제억제화합물,이의제조방법및이를함유하는약제학적조성물
US5461067A (en) * 1993-02-25 1995-10-24 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
SI0900210T1 (pt) 2005-08-31
NO984900L (no) 1998-12-21
CZ337398A3 (cs) 1999-01-13
NZ509046A (en) 2002-05-31
AU2385997A (en) 1997-11-12
CN1319587A (zh) 2001-10-31
IL126381A0 (en) 1999-05-09
EA199800899A1 (ru) 1999-10-28
TW409125B (en) 2000-10-21
CA2510945A1 (en) 1997-10-30
FR05C0030I1 (pt) 2005-08-12
NO984900D0 (no) 1998-10-21
HUP9901612A3 (en) 2000-06-28
DE69732483T2 (de) 2005-07-28
FR05C0030I2 (fr) 2007-04-27
NZ332118A (en) 2001-02-23
WO1997040029A1 (en) 1997-10-30
CN1082508C (zh) 2002-04-10
BR9701877A (pt) 1998-09-29
NO313330B1 (no) 2002-09-16
HK1075043A1 (en) 2005-12-02
CN1616453A (zh) 2005-05-18
IL126381A (en) 2001-08-26
HUP9901612A2 (hu) 1999-08-30
AU706183B2 (en) 1999-06-10
HK1018788A1 (en) 2000-01-07
DE122005000003I1 (de) 2005-05-25
JP3174347B2 (ja) 2001-06-11
AR006720A1 (es) 1999-09-08
CN1310905C (zh) 2007-04-18
EP0900210A1 (en) 1999-03-10
DE69732483D1 (de) 2005-03-17
CA2510945C (en) 2007-01-16
NL300203I1 (nl) 2005-10-03
MY114457A (en) 2002-10-31
ES2238720T3 (es) 2005-09-01
CY2596B2 (en) 2010-03-03
CN1216539A (zh) 1999-05-12
NZ509045A (en) 2002-09-27
NO2005010I1 (no) 2005-05-02
EP0900210B1 (en) 2005-02-09
CZ296135B6 (cs) 2006-01-11
EA001794B1 (ru) 2001-08-27
CA2250840C (en) 2006-07-04
ATE288903T1 (de) 2005-02-15
CA2250840A1 (en) 1997-10-30
JPH11511177A (ja) 1999-09-28
LU91189I2 (fr) 2005-10-03
CN1193010C (zh) 2005-03-16
NL300203I2 (nl) 2005-11-01
CA2568104C (en) 2009-08-04
CA2568104A1 (en) 1997-10-30
SK285048B6 (sk) 2006-05-04
DK0900210T3 (da) 2005-05-02
SK145298A3 (en) 1999-06-11
LU91189I9 (pt) 2018-12-27
HU224125B1 (hu) 2005-05-30

Similar Documents

Publication Publication Date Title
PT900210E (pt) Derivados azahexano heterociclicos com actividade antviral
PT818454E (pt) Derivados de benzimidazole com actividade anti-histaminica
DE69720051D1 (de) Harnstoffderivate
DK1005446T3 (da) N-aroylphenylalaninderivater
ATE235220T1 (de) Resorcinderivate
ATE323682T1 (de) Aryl-pyrimidin-derivate
ID22781A (id) Turunan-turunan nikotinamida
DK0891332T3 (da) 6-phenylpyridyl-2-aminderivater
DE69817186D1 (de) Diaminorhodamin-derivate
IS4800A (is) Nýjar 19-nor-pregnene afleiður
NO981946D0 (no) Imidazoquinazolin-derivater
DE69732576D1 (de) Tetrahydrobenzindolon-derivate
ATE255098T1 (de) Substituierte chromanderivate
ATE440854T1 (de) 5-deoxy-cytidin-derivate
ATE255099T1 (de) Substituierte chromanderivate
NO954323D0 (no) Heterocykliske derivater
FI970110A0 (fi) Helico-bakteerin vastaisia heterosyklisiä atsolonijohdannaisia
IS5026A (is) 2-metoxýfenýlpíperasín afleiður
DE69829682D1 (de) Cis-disubstituierte aminocycloalkyl-pyrrolidin-derivate
DE69828780D1 (de) Amidinocamptpthecin-derivate
NO981495L (no) Fenoksymetylpiperidin-derivater
DK0966437T3 (da) 5-Aroylnaphthalenderivater
DK1015447T3 (da) Piperidinylmethyloxazolidinonderivat
DE69710921T2 (de) Heterocyclische substituierte pyrrolidinamid-derivate
PT1020448E (pt) Aril-heterociclos com actividade herbicida